+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cyclosporine Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997578
  • Report
  • March 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence


  • AbbVie Inc.
  • Apotex Inc.
  • Eon Labs
  • Novartis Inc.
  • Santen Incorporated.
The global cyclosporine drug market was anticipated to grow with a CAGR of nearly 4.1% during the forecast period. Growing prevalence of target diseases such as inflammatory and autoimmune diseases, the presence of strong pipeline, and supportive government legislation for disease awareness are some of the key factors driving the growth of this market. As per the World Psoriasis Day consortium, around 25 million people worldwide that account for 2 to 3 percent of the total population have psoriasis. The high burden of disease and the emergence of multi-drug resistant pathogens have been augmenting the market.

Increasing uses of cyclosporine drugs in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis is expected to boost this market growth. Cyclosporine works by suppressing the immune system’s responses. By reducing the immune response, cyclosporine prevents the immune system from attacking healthy tissues. In addition, the development of different topical, as well as sustained release formulations using generic drugs in order to improve ease of drug delivery and enhance therapeutic efficacy at the desired site, are expected to propel the growth of cyclosporine drugs market during the forecast period.

Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in the field of cyclosporine drugs. Furthermore, these players focus on personnel training and R&D investments in order to capture a larger share in the market. However, lack of awareness of target disease in developing regions may hamper business growth in the future.

Key Market Trends

Rheumatoid Arthritis Shows Lucrative Market Growth and is Expected to Continue the Same during the Forecast Period
  • Rheumatoid arthritis accounted for the largest segment in the global cyclosporine drugs market through the forecast period owing to rising prevalence of rheumatoid arthritis. This can cause stiffness, swelling and joint pain which may lead to chronic pain and inability to perform daily activities. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.
  • According to the World Health Organization, more than 23 million people live with rheumatoid arthritis. Thus, the rheumatoid arthritis segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and low price of biosimilar and generic drugs for the target disease are supplementing the growth of the segment. Introduction of off-label cyclosporine drugs in the treatment of rheumatoid arthritis is poised to create a significant shift in prescription patterns.
  • Moreover transplant rejection prophylaxis is expected to witness the healthy growth rate in the segment through the forecast period. Upsurge in the demand for transplantations will further boost the market growth. According to the Health Resources & Services Administration and the U.S. Department of Health and Human Services, 36,528 transplants were performed in 2018 and more than 113,000 people were in need of transplants as of January 2019. Reduction of transplant rejection can be possible through the use of cyclosporine drugs, further boosting the segment growth.
The North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America is leading owing to the presence of major market players. Furthermore, factors such as increasing prevalence of autoimmune diseases, treatment cost, technological advancements, and product launches are expected to drive the regional growth. Also, various government initiatives aimed at prevention and treatment of target disease. For instance, National Institute of Allergy and Infectious Disease supports the research in collaboration with National Toxicology Program. This initiative is focused on interventions & services that raise awareness and increase access to treatment & preventive measures which pave the way to regional growth for the cyclosporine drugs market.

The Asia Pacific market for cyclosporine drugs is anticipated to be the fastest growing region over the forecast period. This can be attributed to factors such as improving healthcare infrastructure, rising patient awareness, and increasing disposable income. Moreover, new market entrants lead to strong competition, is expected to play an important role in providing growth platform to this regional market over the next few years.

Competitive Landscape

The market for cyclosporine is moderately competitive and consists of the global as well as local players. The moderate competitive environment is marked by key players extensively deploying sustainability strategies.Novartis Inc., Allergan, Sun Pharmaceuticals, Apotex Inc., Teva Pharmaceuticals, AbbVie Inc., Santen Incorporated and Sun Pharma., are some of the notable key players in the cyclosporine drugs market.

These companies are facing stiff generic competition, as several marketed products have lost patents and cheaper alternatives to branded drugs are available in the market. Companies are adopting competitive strategies such as regional expansions, new product development, and strategic collaborations to gain an advantage. For instance, in May 2018, Teva Pharmaceuticals launched of Teva-cyclosporine ophthalmic emulsion, the first generic version of Restasis in Canada for the treatment of dry eye disease.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • AbbVie Inc.
  • Apotex Inc.
  • Eon Labs
  • Novartis Inc.
  • Santen Incorporated.
1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Target Disease
4.2.2 Increase In Potential Clinical Pipeline Candidates
4.2.3 Well-Defined Regulatory Guidelines
4.3 Market Restraints
4.3.1 Lack of Awareness of Target Disease In Developing Regions
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Indication
5.1.1 Transplant Rejection Prophylaxis
5.1.2 Rheumatoid Arthritis
5.1.3 Psoriasis
5.1.4 Autoimmune Myasthenia Gravis
5.1.5 Dry Eye
5.1.6 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.3 Apotex Inc.
6.1.4 Eon Labs
6.1.5 Mayne Pharma Group Limited
6.1.6 McKesson Medical-Surgical Inc.
6.1.7 Novartis Inc.
6.1.8 Santen Incorporated.
6.1.9 Sun Pharmaceuticals
6.1.10 Teva Pharmaceuticals

Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Apotex Inc.
  • Eon Labs
  • Mayne Pharma Group Limited
  • McKesson Medical-Surgical Inc.
  • Novartis Inc.
  • Santen Incorporated.
  • Sun Pharmaceuticals
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown